Imugene (ASX:IMU) a clinical stage immuno-oncology company, has announced the appointment of Dr Mark Marino as its chief medical officer (CMO).
Dr Marino will lead the company’s global clinical development, regulatory and medical monitoring activities.
Dr Marino has held senior level clinical development, leadership and CMO positions at top-tier pharmaceutical companies, including Daiichi-Sankyo, Hoffman-La Roche AG, and Novartis Pharmaceuticals.
In his previous roles, Dr Marino headed teams in oncology, cardiology, endocrinology and rare-diseases, where he was responsible for clinical development through to commercialisation and life cycle management.
Prior to joining the pharmaceutical industry, Dr Marino spent 7 years with the US Military’s Walter Reed Army Institute of Research, the Walter Reed Army Medical Center and the Uniformed Services University of the Health Sciences.
Dr Marino holds a Medical Doctor degree from the Albert Einstein College of Medicine and a Bachelor of Science in Chemistry from the United States Military Academy.
Welcoming Dr Marino, Imugene managing director and CEO Leslie Chong said, “We look forward to the valuable contribution Dr Marino will make to advance our important immuno-oncology programs and are very pleased someone with his track record and experience is joining Imugene as Chief Medical Officer.
"Based in the USA, Dr Marino will support our global clinical development activities as well as our interactions with regulatory agencies and other key stakeholders. His commercial drug development experience, including his contribution in obtaining regulatory approval of a number of innovative new therapies will be very important in supporting Imugene in the rapid development of its expanded pipeline of immuneoncology therapeutics aimed at addressing areas of high unmet need.”
Dr Marino added, “Imugene has an exciting clinical portfolio of promising immuneoncology candidates. I am excited to be joining the Company at this pivotal stage in its development and look forward to working with the team to help bring new medicines to market, which have the potential to meaningfully improve millions of patients’ lives.”